Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NTP lead review

This article was originally published in The Rose Sheet

Executive Summary

National Toxicology Program requests final public comments on seven nominees for listing in the 11th Report on Carcinogens, including lead, which is found in some "traditional" cosmetics, according to the agency. Comments will be accepted for 60 days from publication of Nov. 6 Federal Register 1notice announcing solicitation. NTP's Board of Scientific Counselors RoC Subcommittee voted to list lead as "reasonably anticipated to be a human carcinogen" Oct. 14 (2"The Rose Sheet" Oct. 20, 2003, p. 8)...

You may also be interested in...



Lead Compounds “Reasonably Anticipated” To Be Carcinogenic – NTP Panel

Lead and all lead compounds should be included in the 11th Report on Carcinogens, a National Toxicology Program Board of Scientific Counselors RoC subcommittee concluded at an Oct. 14 meeting in Washington, D.C

Japan's BioComo Pursues Novel Ligand Approach To Immuno-Oncology

Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.

China Uses Old To Fight New As Repurposed Drugs Take Coronavirus Role

Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.

UsernamePublicRestriction

Register

RS011661

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel